|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC01133 |
Gene summary for LINC01133 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC01133 | Gene ID | 100505633 |
| Gene name | long intergenic non-protein coding RNA 1133 | |
| Gene Alias | LINC01133 | |
| Cytomap | 1q23.2 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 100505633 | LINC01133 | GSM4909282 | Human | Breast | IDC | 1.83e-29 | 5.82e-01 | -0.0288 |
| 100505633 | LINC01133 | GSM4909290 | Human | Breast | IDC | 1.74e-06 | 2.07e-01 | 0.2096 |
| 100505633 | LINC01133 | GSM4909315 | Human | Breast | IDC | 2.01e-50 | 9.21e-01 | 0.21 |
| 100505633 | LINC01133 | GSM4909316 | Human | Breast | IDC | 2.74e-18 | 8.08e-01 | 0.21 |
| 100505633 | LINC01133 | CCI_1 | Human | Cervix | CC | 1.14e-10 | 6.12e-01 | 0.528 |
| 100505633 | LINC01133 | CCI_3 | Human | Cervix | CC | 5.92e-17 | 5.47e-01 | 0.516 |
| 100505633 | LINC01133 | Tumor | Human | Cervix | CC | 2.16e-41 | 6.83e-01 | 0.1241 |
| 100505633 | LINC01133 | sample1 | Human | Cervix | CC | 3.25e-05 | 2.13e-01 | 0.0959 |
| 100505633 | LINC01133 | sample3 | Human | Cervix | CC | 1.06e-53 | 6.94e-01 | 0.1387 |
| 100505633 | LINC01133 | T1 | Human | Cervix | CC | 1.69e-04 | 1.52e-01 | 0.0918 |
| 100505633 | LINC01133 | T3 | Human | Cervix | CC | 3.99e-56 | 7.15e-01 | 0.1389 |
| 100505633 | LINC01133 | HTA11_2487_2000001011 | Human | Colorectum | SER | 5.83e-05 | 3.15e-01 | -0.1808 |
| 100505633 | LINC01133 | HTA11_347_2000001011 | Human | Colorectum | AD | 4.29e-09 | 4.11e-01 | -0.1954 |
| 100505633 | LINC01133 | HTA11_2112_2000001011 | Human | Colorectum | SER | 4.54e-02 | 5.19e-01 | -0.2196 |
| 100505633 | LINC01133 | HTA11_866_2000001011 | Human | Colorectum | AD | 5.87e-03 | 1.39e-01 | -0.1001 |
| 100505633 | LINC01133 | LZE2T | Human | Esophagus | ESCC | 2.11e-08 | 1.32e+00 | 0.082 |
| 100505633 | LINC01133 | LZE5T | Human | Esophagus | ESCC | 1.39e-03 | 7.32e-01 | 0.0514 |
| 100505633 | LINC01133 | LZE20T | Human | Esophagus | ESCC | 1.54e-05 | 3.88e-01 | 0.0662 |
| 100505633 | LINC01133 | LZE21D1 | Human | Esophagus | HGIN | 5.18e-05 | 4.81e-01 | 0.0632 |
| 100505633 | LINC01133 | LZE22D1 | Human | Esophagus | HGIN | 6.54e-07 | 7.14e-01 | 0.0595 |
| Page: 1 2 3 4 5 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |